Journal of Clinical Oncology, Vol 3, 1535-1540, Copyright © 1985 by American Society of Clinical Oncology
4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma
HS Hochster, MD Green, J Speyer, E Fazzini, R Blum and FM Muggia
Doxorubicin provides the most consistent response rate in hepatocellular
carcinoma. We therefore initiated a trial with its analog 4'epidoxorubicin.
Eighteen patients, all without prior treatment, were given the drug as a
single agent every 3 weeks with dose escalation whenever possible. Five
patients were treated by six- hour infusion and 13 by intravenous (IV)
bolus injection, with the median dose being 90 mg/m2. The patients were of
diverse ethnic background and included some with underlying cirrhosis and
hepatitis B surface antigenemia. Three patients had partial remissions (6,
12, 48 weeks) for a response rate of 17%. Four patients also had prolonged
stable disease (14, 26, 27, 38 weeks). Toxicity was mild, although cardiac
toxicity developed in three patients at 685, 825, and 1,460 mg/m2
cumulative dose. The response to 4'epidoxorubicin in this study appears to
be equivalent to the reported response rates for doxorubicin, with
decreased toxicity.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
